Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established specific guidelines for the use of ESAs. These guidelines emphasize the importance of using the lowest effective dose to achieve target hemoglobin levels and recommend discontinuing ESA therapy once the anemia is corrected. They also advise against using ESAs in patients with certain cancers unless absolutely necessary.
